AUTHORS
Guillermo Garcia-Manero, MD, Gary J. Schiller, MD2, Tian Zhang, MD PhD3, Samuel Urrutia, MD, MS4, Uma Borate, MBBS, MSc5, James K. McCloskey, MD6, Hetty Carraway, MD, MBA7, Yazan F. Madanat, MD8, Kiran Naqvi9, Harry Erba, MD, PhD10, Bradley D. Hunter11, Lixia Wang, PhD12, Toufigh Gordi, PhD, MBA13, Alison Hannah, MD14, Lewis R Silverman, MD15
AFFILIATIONS
1 MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
2 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
3 Stanford University, Stanford Cancer Center, Palo Alto, California, United States
4 Washington University in St Louis, St Louis, Missouri, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 Hackensack University Medical Center, Hackensack, New Jersey, United States
7 The Cleveland Clinic, Cleveland, Ohio, United States
8 UT Southwestern Medical Center, Dallas, Texas, United States
9 University of California Irvine, Irvine, California, United States
10 Duke University, Durham, North Carolina, United States
11 Intermountain LDS Hospital, Canyons Regions, Utah, United States
12 Rigel Pharmaceuticals Inc., South San Francisco, California, United States
13 Rigel Pharmaceuticals Inc., South San Francisco, California, United States
14 Rigel Pharmaceuticals Inc, South San Francisco, California, United States
15 Icahn School of Medicine at Mount Sinai,, New York, New York, United States
ABSTRACT
Introduction: Therapeutic options are limited for previously treated, transfusion-dependent (TD) LR-MDS patients (pts). R289 is an oral pro-drug of R835, a TLR4 and IL-1R-dependent cytokine release inhibitor, that may suppress inflammation and leukemic stem/progenitor cell function, restoring hematopoiesis in MDS. An ongoing dose escalation/dose expansion study evaluates R289 in LR-MDS (NCT05308264). We present updated safety, PK, biomarker and efficacy.
Methods: Eligible pts were ≥18 years old with R/R LR-MDS IPSS-R score ≤3.5 and either symptomatic anemia (hemoglobin ≤9.0 g/dL, no RBC transfusions within the prior 16 weeks [w] [NTD] or TD-anemia (≥2 units [u] RBCs within the prior 16 w). Baseline (BL) RBC transfusion burden (TB) within the prior 16w was defined as high (HTB, ≥8u RBCs) or low (LTB, 2-7u RBCs). A 3+3 design was used to determine the recommended doses for expansion. In the dose escalation phase, R289 was administered orally at 6 dose levels in 28-day cycles (250, 500, 750 mg QD; 250, 500 mg BID, and 500/250 mg QD split dose), with 2 doses selected for the dose expansion: 500mg QD and BID.
Results: As of 16 July 2026, 64 pts were enrolled in the trial (33 dose escalation; 31 dose expansion). Median age (n=64) was 75 (55% ≥ age 75); 61% males. Baseline IPSS-R category was very low (6%), low (59%), intermediate (23%) or missing (12%); 31% were ring sideroblast positive. Median number of prior therapies was 3 (range 1-8); prior therapies (n=63) included luspatercept 84%, ESA 83%, azacitidine 38%, an investigational agent 29%, decitabine 24% and imetelstat 21%. At BL, 56 pts were TD: 35 pts (63%) were HTB, 21 pts (38%) were LTB; 2 pts were NTD (6 recently enrolled patients had incomplete pre-study transfusion data). BL absolute neutrophil count <1×109/L in 13 pts (20%). BL platelets <100×109/L in 15 pts (23%). At the data cutoff, 32 pts (50%) had discontinued treatment. Median time on therapy was 4.2 months (m) (range 0.8-36m). One dose-limiting toxicity (DLT) occurred at 750 mg QD (reversible grade [G]3 ALT/G4 AST increase) in the dose escalation phase. No DLTs occurred in the dose expansion phase. The most frequent (≥20%) treatment emergent adverse events (TEAEs; n=64) were diarrhea (n=20, 31%) and cough (n=14, 22%),all G1/2. At the dose expansion doses (n=41; 500mg QD [n=21] and 500mg BID [n=20]), common (≥20%) all grade TEAEs included diarrhea (14.3% vs 50%), constipation (0% vs 30%), nausea (5% vs 25%), cough (19% vs 20%), and peripheral edema (5% vs 20%). G3/4 TEAEs in these dose groups (>5%) included anemia (19% vs 0%), platelet count decrease (14% and 0%), hyperglycemia, UTI, pneumonia and sepsis (all 10% vs 0%). AEs leading to study drug discontinuation occurred in 4 pts, all in the dose escalation phase.
In dose escalation, 27 pts had ≥16w follow-up (f/u); of the 6 pts with <16w f/u: AE (n=2), lack of benefit (n=2), PI decision (n=1), and withdraw consent (n=1). No pts receiving 250 mg QD (n=3) or 250 mg BID (n=6, 1 NTD) achieved an RBC-TI. For pts receiving doses ≥500 mg QD in the dose escalation phase, 6 pts (33%) achieved RBC-TI for >8 w (500 mg QD [1/3], 750 mg QD [2/5], 500/250 mg QD [1/5]), and 500 mg BID [2/5]. For 16w and 24w RBC-TI, 4 and 3 patients met this threshold. Median time to onset of RBC-TI was 2.2m (range 0.03-6.8m). Median duration of RBC-TI was 24.3w (range 12.4-143.3+). One LTB pt achieving TI (750 mg QD) also attained a marrow complete response (BL blasts: 4%). Steady-state R835 concentrations in both 500 mg QD and BID dose cohorts achieved levels known to inhibit cytokine release after LPS challenge, however R835 concentrations stayed consistently within the desired range over the dosing period at the 500 mg BID dose (not the 500 QD dose). 29-panel ELISA biomarker analysis was performed (n=32). Comparison of responders (n=7) vs non-responders (n=25) at Cycle 2 Day 1 showed a 44% vs 0% decline in IFN-g and a 30% vs 0% increase in IL-6; small sample size precludes statistical significance. Biomarker analysis on-going.
Conclusions: R289 was well-tolerated in this elderly, heavily pretreated LR-MDS population, the majority of whom were HTB at BL. R835 levels in the 500 mg BID dose cohort showed longer duration of R835 concentrations in a range found to decrease cytokine levels in an LPS challenge study. The randomized comparison of 2 doses in the dose expansion showed a similar, highly tolerable safety profile; efficacy for the dose expansion data will be presented.
DISCLOSURES
Guillermo Garcia-Manero, MD: Abbvie - Research Funding; Novartis - Research Funding; Rigel - Research Funding; GSK - Research Funding; Curis - Research Funding; BMS - Research Funding; Chordia - Research Funding; AstraZeneca - Research Funding; Genentech - Research Funding; Zentalis - Research Funding; Taiho - Research Funding; Ascentage - Research Funding; Servier - Research Funding; Takeda - Research Funding; BMS - Patents & Royalties